HilleVax, Inc.

NasdaqGS HLVX

HilleVax, Inc. Goodwill for the quarter ending September 30, 2024: USD 0.00

HilleVax, Inc. Goodwill is USD 0.00 for the quarter ending September 30, 2024, a 0.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

HilleVax, Inc. Goodwill for the quarter ending September 30, 2023 was USD 0.00.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqGS: HLVX

HilleVax, Inc.

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street
Employees	90
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Key trends

Past 5 years